NorthWest Biotherapeutics Inc (NWBO)

[gnawkz]

Would the Toll-Like Receptors that were also injected into patients be the primary reason why the DC Vaccines utilized by Linda be more effective versus the current standard used in the Phase III trial?

In contrast, we administered the Toll-like receptor (TLR) agonists, imiquimod or poly ICLC, following intradermal injections of ATL-DC to induce DC maturation in vivo. We previously demonstrated in pre-clinical models that the utilization of TLR agonists could enhance the survival and trafficking of DC in situ and enhance the priming of tumor antigen-specific T lymphocytes 31. The findings from this current study suggest that the induction of patient-specific anti-tumor immunity using ATL-DC vaccination and in situ maturation with TLR agonists may represent a preferred formulation for DC-based therapies.

I think it is important to stress that this test is different and not an apple to apple comparison. In addition, 28 patients is not a representative sample. Numerous treatments have shown considerable success in a small sample size only to fail in a larger test.

Maybe, Linda Liau has developed a higher understanding of GBM since the initial trials of DCVax-L and thus was able to select even better patients for this trial? Is it likely, probably not. Is it possible, yes.

There are numerous other reasons that can easily explain why it is possible Linda's DC Vaccines look better at the moment.

Whether it is truly better for the current GBM population can only be rightfully determined through a proper sized, double blind, trial. Anything else can be categorized into hypotheses.